The portal for rare diseases and orphan drugs.
作者信息
Singh Jatinder
机构信息
Department of Pharmacology, Government Medical College, Amritsar, India.
出版信息
J Pharmacol Pharmacother. 2013 Apr;4(2):168-9.
Abstract
摘要
相似文献
1
The portal for rare diseases and orphan drugs.
J Pharmacol Pharmacother. 2013 Apr;4(2):168-9.
2
[FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
Ideggyogy Sz. 2016 Jan 30;69(1-2):37-45. doi: 10.18071/isz.69.0037.
3
Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
Therapie. 2020 Apr;75(2):133-139. doi: 10.1016/j.therap.2020.02.003. Epub 2020 Feb 13.
4
Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.
Drugs. 2018 Mar;78(4):399-410. doi: 10.1007/s40265-018-0882-x.
5
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Orphanet J Rare Dis. 2017 Jan 5;12(1):1. doi: 10.1186/s13023-016-0551-7.
6
Orphan drugs for rare diseases: is it time to revisit their special market access status?
Drugs. 2012 Jul 30;72(11):1437-43. doi: 10.2165/11635320-000000000-00000.
7
Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int. 2007 Feb;16(87):36-42.
8
Drugs for rare diseases: influence of orphan designation status on price.
Appl Health Econ Health Policy. 2011 Jul 1;9(4):275-9. doi: 10.2165/11590170-000000000-00000.
9
Pediatric Orphan Drug Indications: 2010-2018.
Pediatrics. 2020 Apr;145(4). doi: 10.1542/peds.2019-3128. Epub 2020 Mar 3.
10
Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Orphanet J Rare Dis. 2016 May 21;11(1):68. doi: 10.1186/s13023-016-0450-y.
引用本文的文献
1
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms.
Int J Technol Assess Health Care. 2025 Apr 22;41(1):e25. doi: 10.1017/S0266462324004720.
2
Systematic Scoping Review of Socioeconomic Burden and Associated Psychosocial Impact in Patients With Rare Kidney Diseases and Their Caregivers.
Kidney Int Rep. 2024 Dec 10;10(3):838-854. doi: 10.1016/j.ekir.2024.12.005. eCollection 2025 Mar.
3
Scoping Review of Economic Analyses of Rare Kidney Diseases.
Kidney Int Rep. 2024 Sep 12;9(12):3553-3569. doi: 10.1016/j.ekir.2024.09.004. eCollection 2024 Dec.
4
Ontology characterization, enrichment analysis, and similarity calculation-based evaluation of disease-syndrome-formula associations by applying SoFDA.
Imeta. 2023 Jan 10;2(2):e80. doi: 10.1002/imt2.80. eCollection 2023 May.
5
Data collection on rare bone and mineral conditions in Europe: The landscape of registries and databases.
Eur J Med Genet. 2023 Dec;66(12):104868. doi: 10.1016/j.ejmg.2023.104868. Epub 2023 Oct 30.
6
Uncovering the Challenges of Rare Diseases: Insights From a Retrospective Cross-Sectional Study in Albania (2005-2022).
Cureus. 2024 Jan 11;16(1):e52091. doi: 10.7759/cureus.52091. eCollection 2024 Jan.
7
Small supernumerary marker chromosomes derived from human chromosome 11.
Front Genet. 2023 Dec 15;14:1293652. doi: 10.3389/fgene.2023.1293652. eCollection 2023.
8
Autoimmune polyglandular syndrome type 4: experience from a single reference center.
Front Endocrinol (Lausanne). 2023 Oct 23;14:1236878. doi: 10.3389/fendo.2023.1236878. eCollection 2023.
9
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases.
Mol Neurodegener. 2023 Aug 7;18(1):52. doi: 10.1186/s13024-023-00639-y.
10
Clinical, Cognitive and Neurodevelopmental Profile in Tetrasomies and Pentasomies: A Systematic Review.
Children (Basel). 2022 Nov 9;9(11):1719. doi: 10.3390/children9111719.
Zotero 插件